Implementing a probabilistic model of Alzheimer’s disease, in place of the current deterministic conceptualization which is driven by the amyloid hypothesis, may lead to an improved understanding of disease biology, as well as accelerated therapeutic development. Giovanni Frisoni, MD, University of Geneva, Geneva, Switzerland, highlights the implications of following a model focused on a probabilistic chain of events, rather than centering amyloid. Prof. Frisoni comments on the need to treat prior to symptom development and target numerous pathologies at once with combination therapy. APOE status is also key in this model and should be considered in all studies of Alzheimer’s disease. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
